Tuesday links: should-have syndrome

Bank sues analyst.  (DealBreaker.com, Big Picture, ClusterStock.com)

Recent changes in asset class correlations.  (Bespoke Investment Group)

The Roche-Genentech deal is going to be a “an expensive, time-consuming affair”.  (Deal Journal)

Two different approaches, two different results:  InBev and Microsoft.  (DealBook)

What can Microsoft (MSFT) do about its languishing stock price?  (Tech Trader Daily)

Some hedge fund stars from 2007 are having a repeat performance in 2008.  (WSJ.com)

An obscure market timing indicator turns positive for the first time in a while.  (Marketwatch.com)

Ten new international sector ETFs.  (24/7 Wall St.)

There is nothing magical about the VIX.  (Daily Options Report)

It has been a really bad quarter for dividends.  (MarketBeat)

Not all financials are ‘poison.’ (Aleph Blog)

Data on ‘naked shorts‘ is hard to come by.  (NakedShorts)

Traders need to deal with “should-have syndrome.”  (TraderFeed)

An interesting job post for a hedge fund.  (Infectious Greed)

The CBO weighs in on the GSE rescue plan.  (Odd Numbers, Curious Capitalist)

What is causing global food inflation?  (Economist’s View)

Are you a fan of Abnormal Returns? Check. Prefer to read our posts via e-mail? Check. A simple sign-up form to receive all of our posts in your inbox. Check.

blog comments powered by Disqus